Michiaki Koga

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Carbohydrate mimicry between human ganglioside GM1 and <i>Campylobacter jejuni</i> lipooligosaccharide causes Guillain–Barré syndrome

Nobuhiro Yuki, Keiichiro Susuki, Michiaki Koga et al. · Proceedings of the National Academy of Sciences · 2004 · 496 citations · Full text

Life Sciences, Immunology, Neurology +17

Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis

Minoru Nakamura, Hisayoshi Kondo, Tsuyoshi Mori et al. · Hepatology · 2006 · 361 citations · Full text

Medicine, Hematology, Immunology +13

Axonal Guillain-Barr� syndrome: Relation to anti-ganglioside antibodies andCampylobacter jejuni infection in Japan

Kazue Ogawara, Satoshi Kuwabara, Masahiro Mori et al. · Annals of Neurology · 2000 · 326 citations

Life Sciences, Neurology, Neuroscience +17

Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside

Nobuhiro Yuki, Mitsunori Yamada, Michiaki Koga et al. · Annals of Neurology · 2001 · 322 citations

Life Sciences, Neurology, Neuroscience +17